Published in Cancer Res on September 21, 2012
High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS One (2013) 1.19
Cytomegalovirus pp71 protein is expressed in human glioblastoma and promotes pro-angiogenic signaling by activation of stem cell factor. PLoS One (2013) 1.04
Dual analysis of the murine cytomegalovirus and host cell transcriptomes reveal new aspects of the virus-host cell interface. PLoS Pathog (2013) 0.99
High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancers. Transl Oncol (2014) 0.80
The oncomodulatory role of human cytomegalovirus in colorectal cancer: implications for clinical trials. Front Oncol (2014) 0.80
Cytomegalovirus in human brain tumors: Role in pathogenesis and potential treatment options. World J Exp Med (2015) 0.78
Human cytomegalovirus-encoded US28 may act as a tumor promoter in colorectal cancer. World J Gastroenterol (2016) 0.77
Expression of Oncogenic Alleles Induces Multiple Blocks to Human Cytomegalovirus Infection. J Virol (2016) 0.76
Mutations in glioblastoma oncosuppressive pathways pave the way for oncomodulatory activity of cytomegalovirus. Oncoimmunology (2013) 0.76
Modeling cytomegalovirus infection in mouse tumor models. Front Oncol (2015) 0.76
Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector. Immunotherapy (2016) 0.76
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 4.58
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol (2004) 2.43
Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A (1990) 2.03
Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol (2003) 1.92
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest (2011) 1.87
Is HCMV a tumor promoter? Virus Res (2010) 1.81
Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res (1992) 1.72
Epidemiology of cytomegaloviral infections: recommendations for prevention and control. Rev Infect Dis (1985) 1.51
Presentation, prognostic factors and patterns of failure in adult rhabdomyosarcoma. Sarcoma (2003) 1.32
Rhabdomyosarcoma. Curr Probl Cancer (2008) 1.20
Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr Top Dev Biol (2011) 1.10
Replication of human cytomegalovirus in a rhabdomyosarcoma cell line depends on the state of differentiation of the cells. Arch Virol (1994) 0.92
Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma. Sarcoma (2012) 0.85
The infection of human primary cells and cell lines by human cytomegalovirus: new tropism and new reservoirs for HCMV. Virus Res (2007) 0.83
Inhibition of p53 transcriptional activity by human cytomegalovirus UL44. Microbiol Immunol (2012) 0.82
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res (2008) 4.64
Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 4.58
TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron (2008) 4.00
Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci (2009) 2.90
Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res (2004) 2.75
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell (2010) 2.59
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res (2006) 2.42
Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol (2004) 2.21
High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol (2003) 2.06
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci (2009) 1.85
Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther (2003) 1.78
Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms. Histopathology (2012) 1.63
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res (2005) 1.63
Designing isoform-specific peptide disruptors of protein kinase A localization. Proc Natl Acad Sci U S A (2003) 1.61
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther (2008) 1.59
Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol (2009) 1.53
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther (2004) 1.51
Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol (2006) 1.50
Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res (2006) 1.47
Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol (2008) 1.47
Emerging functions of microRNAs in glioblastoma. J Neurooncol (2009) 1.44
Comparative mutational profiling in the assessment of lung lesions: should it be the standard of care? Ann Thorac Surg (2010) 1.44
Antisense transcription in the human cytomegalovirus transcriptome. J Virol (2007) 1.40
microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle (2010) 1.40
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther (2006) 1.32
Neurotrophin-dependent dendritic filopodial motility: a convergence on PI3K signaling. J Neurosci (2008) 1.32
Inducible site-specific recombination in neural stem/progenitor cells. Genesis (2009) 1.31
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther (2008) 1.28
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res (2005) 1.26
MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol (2013) 1.20
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther (2005) 1.16
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther (2009) 1.16
The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther (2002) 1.14
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther (2008) 1.12
Germline variation controls the architecture of somatic alterations in tumors. PLoS Genet (2010) 1.11
Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets (2007) 1.11
Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget (2014) 1.11
Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res (2012) 1.11
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol (2009) 1.10
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
A mathematical model for pattern formation of glioma cells outside the tumor spheroid core. J Theor Biol (2009) 1.10
In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology (2002) 1.09
A seizure-prone phenotype is associated with altered free-running rhythm in Pten mutant mice. Brain Res (2007) 1.09
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Quantitative analysis of complex glioma cell migration on electrospun polycaprolactone using time-lapse microscopy. Tissue Eng Part C Methods (2009) 1.08
Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res (2005) 1.07
Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther (2013) 1.07
Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther (2011) 1.05
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol (2012) 1.03
MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia (2002) 1.03
Neurofibromin is required for barrel formation in the mouse somatosensory cortex. J Neurosci (2008) 1.03
In-training factors predictive of choosing and sustaining a productive academic career path in neurological surgery. Neurosurgery (2012) 1.03
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest (2002) 1.03
Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res (2011) 1.02
miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci Signal (2013) 1.02
Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther (2004) 1.02
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther (2012) 1.02
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res (2014) 1.00
Lack of epidural pressure change with neck flexion in a patient with Hirayama disease: case report. Neurosurgery (2009) 0.99
Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res (2013) 0.99
Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med (2003) 0.99
Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr (2012) 0.99
Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother (2009) 0.98
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res (2010) 0.97
PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res (2003) 0.97
C2/C3 pathologic fractures from polyostotic fibrous dysplasia of the cervical spine treated with percutaneous vertebroplasty. Eur Spine J (2007) 0.97
A comparison of outcomes between open and laparoscopic surgical repair of recurrent inguinal hernias. Surg Endosc (2011) 0.97
Thigh mass in a 73-year-old man. Clin Orthop Relat Res (2008) 0.96
The association between Chance fractures and intra-abdominal injuries revisited: a multicenter review. Am Surg (2005) 0.96
A retrospective cohort-matched comparison of conscious sedation versus general anesthesia for supratentorial glioma resection. Clinical article. J Neurosurg (2010) 0.96
The status of gene therapy for brain tumors. Expert Opin Biol Ther (2007) 0.95
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
PAX-8 expression in cutaneous ciliated cysts: evidence for Müllerian origin. Am J Dermatopathol (2014) 0.94
Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer (2002) 0.93
Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clin Cancer Res (2012) 0.92
NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms. Mod Pathol (2013) 0.92
HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and invasiveness via PDGFR-alpha activation. Oncotarget (2014) 0.91
The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod Pathol (2012) 0.91
Functional response of tumor vasculature to PaCO2: determination of total and microvascular blood volume by MRI. Neoplasia (2003) 0.91
Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther (2009) 0.91
Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther (2002) 0.91
Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene. Mol Ther (2007) 0.90
High affinity hydroxypiperidine analogues of 4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidine for the dopamine transporter: stereospecific interactions in vitro and in vivo. J Med Chem (2003) 0.90
Clinical and economic outcomes of low-field intraoperative MRI-guided tumor resection neurosurgery. J Magn Reson Imaging (2011) 0.89
Pain and wound healing in surgical patients. Ann Behav Med (2006) 0.88